Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment

Abstract

Coincidence of COPD and heart failure (HF) is challenging as both diseases interact on multiple levels with each other, and thus impact significantly on diagnosis, disease severity classification, and choice of medical therapy. The current overview aims to educate caregivers involved in the daily management of patients with HF and (possibly) concurrent COPD in how to deal with clinically relevant issues such as interpreting spirometry, the potential role of extensive pulmonary function testing, and finally, the potential beneficial, but also detrimental effects of medication used for HF and COPD on either disease.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

“…481 Spirometry should be performed when patients have been stable and euvolaemic for at least 3 months, to avoid the confounding effect of pulmonary congestion causing external obstruction of alveoli and bronchioles. 482 Both correctly and incorrectly labelled COPD are associated with worse functional status and a worse prognosis in HFrEF. Beta-blockers are only relatively contraindicated in asthma, but not in COPD, although a more selective b1-adrenoceptor antagonist (i.e.…”

Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial

“…COPD affects about 5-10% of the adult population worldwide [2], and develops on average about 10 years earlier than HF (i.e. at 55 vs. 65 years of age) [3], which is less common (an estimated prevalence of 1-3%) but carries a significantly worse prognosis. Thus, a causative role has been generally investigated for COPD in the development and progression of HF.…”

İleri evre kalp yetersizliği rehberi

“…[17] Bunun önlenmesi için KY'li hastalara, en az 3 ay övolemik kaldıktan sonra dekompanse KY yok iken spirometri yapılması öne-rilmektedir. [17,109] KOAH'lı KY hastalarının KY ve KOAH kılavuz-larına göre tedavi edilmesi önerilmektedir. [17,107] Burada dikkat edilmesi gereken hususlardan biri, KY tedavisinin olmazsa olmazı beta blokerleri kullanır-ken, beta 2 agonist-bronkodilatör etkinliğin azalmasına bağlı KOAH'lı hastalarda bronkospazmın tetiklenebilmesidir.…”